Article

Phase II Trial of Intravenously Administered AMD3100 (Plerixafor) for Stem Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Following a Lenalidomide Based Initial Therapy

Biology of Blood and Marrow Transplantation (Impact Factor: 3.35). 02/2012; 18(2):S247-S247. DOI: 10.1016/j.bbmt.2011.12.129
0 Followers
 · 
97 Views